Shareholders May Not Be So Generous With TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation And Here's Why
Key Insights TOT BIOPHARM International will host its Annual General Meeting on 26th of June Total pay for CEO Jun Liu includes CN¥3.73m salary The total compensation is similar to the average for
Dongyao Pharmaceutical-B (01875.HK) proposes to adopt the 2024 Restricted Share Award Scheme
Gelonghui, May 29丨Dongyao Pharmaceutical-B (01875.HK) issued an announcement. The board of directors recommended the adoption of the 2024 restricted share award plan, which is valid for ten (10) years from the date of adoption. This will enable the company to attract and retain necessary talents, motivate group employees, and enable the company to flexibly grant share-based rewards on existing shares in addition to new shares.
TOT BIOPHARM International Company Limited (HKG:1875) Soars 28% But It's A Story Of Risk Vs Reward
TOT BIOPHARM International Company Limited (HKG:1875) shareholders would be excited to see that the share price has had a great month, posting a 28% gain and recovering from prior weakness. Not all
Dongyao Pharmaceutical-B: CDMO achieved remarkable results in strategic transformation and officially turned losses into profits
Dongyao Pharmaceutical-B (1875.HK) performance progress has reached a new milestone. On May 10, the company announced its results for the first quarter of 2024. Operating revenue increased 68% year over year to about 223 million yuan, and net profit was about 7.409 million yuan. The company fully turned a loss into a profit. According to the announcement, the increase in revenue was mainly due to continued growth in the CDMO/CMO business and a sharp increase in sales of self-developed products. Looking back at the company's past performance, it can be seen that Dongyao Pharmaceutical-B's performance has grown rapidly in just a few years after fully transforming and expanding its CDMO business in 2021. This transformation not only enabled the company's
Dongyao Pharmaceutical-B (01875) achieved net profit of about 7.409 million yuan in the first quarter, turning a year-on-year loss into profit
Dongyao Pharmaceutical-B (01875) announced its results for the first quarter of 2024. Operating revenue increased 68% year on year to about 223 million yuan, and net profit was about 7.409 million yuan, turning a year-on-year loss into a profit.
TOT BIOPHARM-B: ANNUAL REPORT 2023
Dongyao Pharmaceutical-B announced that it will achieve revenue of 781 million yuan in 2023, a 77% year-on-year increase
Dongyao Pharmaceutical-B (01875) announced its 2023 results. The group's revenue was approximately RMB 781 million, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630 million, an increase of 107% over the previous year. The main contribution came from a sharp increase in sales performance of the core product, Park Hsin Ting (bevacizumab injection). CDMO/CMO business revenue was RMB 141 million, up 94% year over year. Since there was no one-time authorization income for the full year of 2023 (RMB 54,151 million for the full year of 2022), excluding this factor, the revenue for the full year of 2023 is the same
Gelonghui Announcements Selected (Hong Kong Stocks) | Fuyao Glass (03606.HK) Announces Annual Results: Net Profit Increased by 18.37% to RMB 5.629 billion, with an estimated capital requirement of RMB 41,016 billion for the full year of 2024
[Today's Focus] Fuyao Glass (03606.HK) announced annual results: net profit increased by 18.37% to 5.629 billion yuan, with an estimated capital requirement of 41,016 billion yuan for 2024 Fuyao Glass (03606.HK) announced annual results. For the year ended December 31, 2023, the company consolidated revenue of RMB 33.161 billion, an increase of 18.02% over the same period of the previous year; achieved profit before tax of RMB 6.715 billion, an increase of 20.38% over the same period of the previous year, and achieved an annual profit of RMB 20.38% over the same period last year 5.629 billion yuan, compared to the previous year
Dongyao Pharmaceutical-B (01875.HK) announced annual results, a sharp increase in revenue of 77%, and the group's hematopoietic capacity continued to increase
Gelonghui March 15 | Dongyao Pharmaceutical-B (01875.HK) announced that in 2023, the Group's revenue was RMB 780,629 thousand, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630,207 thousand, an increase of 107% over the previous year. The main contribution was due to a significant increase in sales performance of the core product Park Xinting (bevacizumab injection). CDMO/CMO business revenue was RMB 140,898 thousand, up 94% year over year. Due to no one-time authorization income for the full year of 2023 (RMB 54,151 thousand for the full year of 2022)
TOT BIOPHARM-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED 31 DECEMBER 2023
Dongyao Pharmaceutical-B (01875.HK) plans to hold a board meeting on March 15 to approve annual results
Gelonghui March 5 | Dongyao Pharmaceutical-B (01875.HK) announced that the company will hold a board meeting on March 15, 2024 (Friday) to consider and approve the Group's annual results for the year ended December 31, 2023, and to deal with other matters.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) is now up more than 8%, and overseas authorized transactions for domestic ADCs are hot
Dongyao Pharmaceutical-B (01875) is currently up more than 8%. As of press release, it is up 8.12% to HK$2.13.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) boosted by more than 23%, ADC innovation and development acceleration agencies previously recommended focusing on ADC CDMO innovative pharmaceutical companies, etc.
Dongyao Pharmaceutical-B (01875) rose more than 23%. As of press release, it was up 21.91% to HK$2.17, with a turnover of HK$2,496 million.
Dongyao Pharmaceutical-B [01875] is now reported at HK$2.17, an increase of 21.91%
As of 13:49, Dongyao Pharmaceutical-B [01875] reported HK$2.17, up HK$0.39 or 21.91% from last year's closing price, with a turnover of HK$170,500, today's highest price of HK$2.2, and the lowest price of HK$1.74. Based on yesterday's closing price, the 10-day average price is HK$1.90 and the 50-day average price is HK$1.90. The current price-earnings ratio is -20.34 times, and the 14-day strength index is 33.93.
Dongyao Pharmaceutical-B (01875.HK)'s revenue in the first three quarters increased 77% to 542 million yuan, and sales of self-developed products increased significantly
Gelonghui November 10 | Dongyao Pharmaceutical-B (01875.HK) announced that in the nine-month period ending September 30, 2023, the Group's revenue increased 77% year-on-year to RMB 542 million, mainly due to the sharp increase in sales of self-developed products and the rapid increase in CDMO/CMO business.
Huajin Securities: ADC innovation and development accelerates focus on Rongchang Biotech (688331.SH) and other related targets
Huajin Securities released a research report saying that due to the complex design of ADC structures, technology platforms are the primary competitive barrier for innovative pharmaceutical companies.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) rose nearly 10%, core product sales revenue increased sharply in the first half of the year, and the CDMO sector continued to rise
Dongyao Pharmaceutical-B (01875) rose nearly 10%. As of press release, it rose 9.94% to HK$1.99 billion, with a total market value of HK$1,538 billion.
TOT BIOPHARM-B: INTERIM REPORT 2023
Dongyao Pharmaceutical-B (01875) Interim Report - Revenue Maintains Triple-Digit Growth
Dongyao Pharmaceutical-B (01875) announced its 2023 interim results. Total revenue for the first half of the year was RMB 328 million, an increase of 80% over the previous year. Excluding the impact of license revenue for the first half of 2022, the revenue growth rate reached 147% year-on-year.
Exploring the dark horse in the ADC CDMO field: Dongyao Pharmaceutical's (01875.HK) performance explosion draws attention
The high increase in revenue and the correction in net cash flow from operating activities clearly depict the company's remarkable achievements in the CDMO field.
No Data